DNLI — Q2 2026 Financial Report Analysis

Denali's second quarter of 2026 was its first as a company with a product on the market. Until March it was a clinical-stage biotech, meaning its drugs were still in human trials and none were approved for sale. AVLAYAH, its Hunter syndrome drug, received FDA accelerated approval on March 24 and brought in $3.6 million of net product revenue after shipping began in April. That is small next to $134.1 million of operating expenses, so the net loss widened slightly to $127.6 million from $124.1 million. The loss grew because interest income fell, not because spending rose: operating expenses were flat and the operating loss narrowed by $4.4 million. The bigger news for the balance sheet came after quarter-end. Denali sold the priority review voucher it received with the approval for $195 million in July, which takes pro forma cash and investments above $1.1 billion.

Key figures

Operating margin isn't shown: with $3.6M of revenue against $134M of costs, the ratio is a meaningless four-digit negative number.

The launch: what $3.6 million does and doesn't tell you

AVLAYAH (tividenofusp alfa) is an enzyme replacement therapy. It supplies the enzyme (iduronate 2-sulfatase) that children with Hunter syndrome (MPS II) lack. Existing enzyme therapies can't cross the blood-brain barrier, the protective lining that keeps most large molecules out of the brain. That leaves the condition's neurological damage untreated. AVLAYAH is fused to Denali's "TransportVehicle," which uses the transferrin receptor to carry the drug into the brain. The press release calls it the first FDA-approved biologic in this class.

Three points shape how to read the first quarter's sales:

• It was a partial ramp, not a steady state. Distribution began in April. Management says interest "tracked ahead of Denali's internal expectations." Published commercial insurance policies now cover more than 50% of covered lives, 14 state Medicaid programs have published coverage, and the field team has reached about 80% of the healthcare organizations that treat eligible patients.
• The label is narrow. AVLAYAH is approved for pediatric patients weighing at least 5 kg, started before advanced neurologic impairment. The adult population is not on the label yet. Expanding to adults is one of the stated goals of the ongoing Phase 2/3 COMPASS study.
• The approval is conditional. Accelerated approval means the FDA approved the drug on a surrogate endpoint, here a reduction of heparan sulfate (a waste sugar that builds up in Hunter syndrome) in spinal fluid. "Continued approval is contingent upon confirmation of clinical benefit" in COMPASS. Until that study reads out, the revenue stream carries regulatory risk that a full approval would not.

What the headline numbers hide

• The cost of goods line is artificially low and will rise. On $3.6M of sales, cost of goods sold was just $93K, which suggests a gross margin above 97%. That figure is flattered by accounting timing: manufacturing costs incurred before approval were already expensed as R&D. Denali holds $12.6M of this previously expensed inventory, which it expects to sell through by January 2027. After that, cost of goods will reflect full manufacturing cost, and reported gross margin will fall even if the business itself hasn't changed.
• Part of the R&D decline was partner money, not lower spending. R&D fell $5.7M year over year. The largest driver was an $8.4M drop in "other" R&D from winding down small-molecule work on BIIB122/DNL151 and DNL343. However, an outside funder of the Phase 2a BEACON study offset $7.6M of R&D this quarter, versus $3.8M a year ago. Denali has received $62.5M of that funder's $75.0M commitment. These offsets are recognized as the work is done and will run out when the commitment is used up, so this cushion is temporary.
• The drop in interest income is partly a new financing cost, not just lower rates. Interest and other income fell $7.9M. Of that, $5.9M is non-cash interest on the $200M Denali received from Royalty Pharma in March. That money appears on the balance sheet as a $205.2M liability, not as equity. In return, Royalty Pharma gets 9.25% of AVLAYAH's worldwide net sales until payments reach 3.0x the funding (2.5x if that cap is reached by Q1 2039). Every future dollar of AVLAYAH sales is therefore worth about 91 cents to Denali, and this interest charge will recur every quarter.
• Cash burn was much larger than the net loss suggests. H1 operating cash outflow was $228.2M, versus a net loss of $256.0M. The gap is mostly non-cash charges, chiefly $46.0M of stock-based compensation, partly offset by working-capital outflows. Accrued liabilities fell $19.1M, and the first receivables ($3.9M) and inventory ($4.1M) appeared on the balance sheet. Receivables roughly equal one quarter of sales, which is normal for a launch billed through specialty distributors.
• Dilution is ongoing. Common shares outstanding rose from 156.2M at year-end to 159.8M. Of that increase, about 2.8M came from employee option exercises and vesting restricted stock units, and 0.75M from the underwriter's option on the December 2025 offering, which closed in January. There are also 28.3M pre-funded warrants, exercisable at $0.01 and effectively already shares, which brings the economic share count to about 188M. The company still has an unused $400M at-the-market facility that would let it sell new shares directly into the market.
• The funding picture is strong, but it was paid for. Cash, equivalents and marketable securities were $940.0M at June 30. The voucher sale adds $195M, and management cites "more than $1.1 billion" pro forma. If burn stays at about $114M a quarter, our estimate is roughly 2.5 years of cash runway, meaning how long the money lasts before Denali has to raise more, assuming no growth in AVLAYAH sales. The company's own statement is more cautious: cash is sufficient for "at least the twelve months" after the filing. It also says it will need "substantial additional funding." About $395M of the cushion came from one-time, non-dilutive sources this year (the royalty deal and the voucher). Neither can be repeated for this product. A second voucher would require a second rare pediatric disease approval.

Pipeline: what changed this quarter

• Setback: the LRRK2 Parkinson's bet failed in its broad population. In May, the Phase 2b LUMA study of BIIB122/DNL151 with Biogen missed its primary and secondary endpoints in early-stage Parkinson's disease, and the partners stopped development in idiopathic (non-genetic) Parkinson's. Denali continues the smaller BEACON study alone, in patients who carry a disease-causing LRRK2 gene variant, with data expected in H1 2027.
• Partner exit: Takeda handed back DNL593 (for frontotemporal dementia caused by GRN mutations), effective June. The company says the decision was "driven by strategic considerations and not related to efficacy or safety data." Denali now carries the program's full cost. It also pushed results from 2026 into 2027 to allow a longer observation period for the neurofilament light chain biomarker.
• Progress: two brain-targeted Alzheimer's programs are now in the clinic. DNL628 (a tau-lowering antisense drug; first patient dosed in March) and DNL921 (an anti-amyloid antibody; trial application submitted in H1 2026). Both rely on the same blood-brain-barrier transport technology as AVLAYAH.

Takeaway: Denali's operating loss improved a little, but that isn't the main story. The approval paid for itself before many patients were treated: the $200M royalty deal and the $195M voucher sale together brought in about $395M of non-dilutive cash. That is roughly 1.7 times the cash Denali burned in the first half. The costs of that cash appear later: 9.25% of all future AVLAYAH sales go to Royalty Pharma, a non-cash interest charge recurs each quarter, and a gross margin flattered by already-expensed inventory ends around January 2027.

Outlook

Management's only financial guidance is Q3 2026 AVLAYAH net revenue of $10.0–12.0 million. Catalysts management has dated:

• Zafinofusp alfa (MPS IIIA / Sanfilippo syndrome type A): BLA submission (the formal application for approval) and potential accelerated approval in 2027. A global Phase 3 confirmatory study is in start-up. This is the nearest second product. If it is approved as a rare pediatric disease, it could also earn another priority review voucher. The filing does not promise one.
• DNL593 (FTD-GRN): Phase 1/2 results in 2027. The FDA granted Orphan Drug Designation in August.
• DNL952 (Pompe disease): initial clinical data in 2027.
• DNL628 (Alzheimer's): initial biomarker data in H1 2027. DNL921 (Alzheimer's): safety and proof-of-concept data in 2027.
• DNL151 BEACON (LRRK2-variant Parkinson's): data in H1 2027.
• AVLAYAH outside the US: EU approval would trigger an extra $75.0M from Royalty Pharma (if it comes by end-2029) and a $24.0M contingent payment that Denali owes to the former shareholders of F-star Gamma, an acquisition from 2018. US approval already triggered a $36.0M milestone to them, which Denali capitalized as an intangible asset. That asset is the source of the new $0.75M quarterly amortization line.

Our read: for the next few quarters, the question is the AVLAYAH revenue ramp, starting with whether Q3 lands within the $10–12M guidance. The one-time cash raises mean the company is not under near-term financing pressure. Almost all of the other pipeline readouts fall in 2027, so 2026 is mostly a test of the launch. Watch three things in the coming quarters: sequential sales growth beyond Q3, the R&D line once the BEACON funding offsets taper, and whether gross margin holds up after the pre-launch inventory is used up around January 2027.